IBO
Impact BioMedical, Inc.
AMEX: IBO · HEALTHCARE · BIOTECHNOLOGY
$0.46
+4.35% today
Updated 2026-09-11
Market cap
$52.83M
P/E ratio
0.56
P/S ratio
1,509.50x
EPS (TTM)
$0.88
Dividend yield
—
52W range
$0 – $1
Volume
0.1M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F3.8
Quality
D4.0
Profitability
C6.7
Valuation
B4/9
Piotroski F-Score
Moderate
-1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Profit margin 2,260.00% — above average
+ Free cash flow $470000.00 — positive
Risks
- Altman Z -1.58 — distress zone
- Revenue declining -57.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $50000.00 | $1.03M | $1.62M | $32000.00 | $35000.00 |
| Net income | $-7.05M | $-4.34M | $-24.71M | $-11.84M | $-699000.00 |
| EPS | — | — | — | — | $0.88 |
| Free cash flow | $-2.52M | $-2.87M | $-5.64M | $-1.89M | $470000.00 |
| Profit margin | -14,102.00% | -420.98% | -1,525.34% | -36,993.75% | 2,260.00% |
Peer comparison
Smart narrative
Impact BioMedical, Inc. trades at $0.46. representing a P/E of 0.56x trailing earnings. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -1.58, it sits in the distress. TTM revenue stands at $35000.00. with profit margins at 2,260.00%.
Frequently asked questions
What is Impact BioMedical, Inc.'s stock price?
Impact BioMedical, Inc. (IBO) trades at $0.46, on a P/E of 0.6x and a P/S of 1,509.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Impact BioMedical, Inc. overvalued?
Impact BioMedical, Inc. carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is Impact BioMedical, Inc.'s revenue?
Impact BioMedical, Inc.'s trailing twelve-month revenue is $35000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Impact BioMedical, Inc.'s Altman Z-Score is -1.58, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio1,509.50x
ROE-112.16%
Beta—
50D MA$0.45
200D MA$0.51
Shares out0.11B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—